Die Dermagnostix GmbH aus Freiburg, spezialisiert auf die Entwicklung molekulardiagnostischer Tests für dermatologische Fragestellungen, erweitert ihr Leistungsportfolio durch die Übernahme und Fortführung der Fluoreszenzdetektor Technologie der Dialunox GmbH i.L. aus Stockach zum 01.07.2025.
Press
Dermagnostix announces acquisition and continuation of the fluorescence detector technology of Dialunox as of July 1st 2025
The Dermagnostix GmbH from Freiburg, specialized on the development of molecular diagnostic tests for dermatology, expands its portfolio by the acquisition and continuation of the fluorescence detector technology of Dialunox GmbH i.L. (Stockach) as of July 1st 2025.
Dermagnostix CEO Prof. Dr. Natalie Garzorz-Stark Wins Innovation Award Dermatology by BVDD e.V.
Natalie Garzorz-Stark, CEO and co-founder of Dermagnostix, has been awarded the Innovation Award Dermatology by BVDD for the groundbreaking approach to revolutionizing dermatological diagnostics with automated molecular tests.
State Parliament President Muhterem Aras and Member of Parliament Nadyne Saint-Cast Visit Dermagnostix in Freiburg
Muhterem Aras and Nadyne Saint-Cast recently visited Dermagnostix. Together with Dermagnostix’ managing directors Natalie Garzorz-Stark and Ludwig Gutzweiler they discussed the challenges and opportunities for healthcare start-ups, highlighting the role of political support for private investments.